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Soluble NKG2D ligands are biomarkers for checkpoint blockade-treated melanoma 
patients 
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Abstract 
The introduction of immune checkpoint blockade into the clinical practice resulted in 
improvement of survival of a significant portion of melanoma patients. Consequently, 
predictive biomarkers of response are needed to optimize patient’s stratification and the 
development of combination therapies. The aim of this study was to determine whether 
levels of soluble NKG2D ligands (MICA, MICB, ULBP1, 2 and 3; sNKG2DLs) in the 
serum of melanoma patients can serve as useful predictors of response to the treatment 
with immune checkpoint blockade. sNKG2DLs were measured by ELISA in baseline and 
post-treatment serum and these results were correlated with the clinical outcome of 
melanoma patients (N=194). The same determinations were performed also in a cohort of 
patients (N=65) treated with either chemotherapy, radiotherapy, or mutated BRAF 
inhibitors (BRAFi). Absence of soluble MICB and ULBP-1 in baseline serum correlated 
with improved survival (OS= 21.6 and 25.3 months and p= 0.02 and 0.01, respectively) 
of patients treated with immunological therapies while detectable levels of these 
molecules were found in poor survivors (OS= 8.8 and 12.1 months, respectively). 
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Multivariate analysis showed that LDH (p<0.0001), sULBP-1 (p=0.02) and sULBP-2 
(p=0.02) were independent predictors of clinical outcome for the cohort of melanoma 
patients treated with immune checkpoint blockade. Only LDH but not sNKG2DLs was 
significantly associated with the clinical outcome of patients treated with standard or 
BRAFi regimens. These findings highlight the relevance of sNKG2DLs in the serum of 
melanoma patients as biomarkers for patients’ stratification and optimization of immune 
checkpoint inhibition regimens. 
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In tumors with different histological origin the adaptive immune response can 




 This concept has 
been further characterized by the demonstration that the nature, location and density of 
tumor-infiltrating lymphocytes (TILs) is associated with the prognosis of cancer patients, 
allowing better staging of disease and consisting in a more reliable prognostic marker 




. Nevertheless, the immunesurveillance of 
tumors is often impaired by immunomodulatory mechanisms occurring at tumor site, 
such as regulatory immunological cell populations (T regulatory cells, Tregs and Myeloid 
Derived Suppressor Cells, MDSCs), the pro-tumor cross-talk between cancer cells and 
tumor microenvironment (TME) and the presence of negative regulatory factors in the 





Immunotherapy aims at circumventing negative immunomodulatory pathways to induce 
potent systemic immunological responses against tumors. 
10
 Antibodies (Abs) that block 
immune checkpoints, such as the anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) and 
the anti-programmed cell death-1 (PD-1) or its ligand (PD-L1), can potentiate or rescue 





clinical activity of immune checkpoints agents has been conclusively demonstrated for 
different types of tumors. 
13, 14, 15, 16, 17,
 
18
 The combination treatment with anti-CTLA-4 
and anti-PD-1 mAbs for metastatic melanoma yielded striking clinical results, leading to 




 The efficacy of this combination is also under evaluation in other 
solid tumors such as lung cancer. 
21
 Nevertheless, similarly to single agent therapies, a 
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proportion of patients do not respond to this combination, thus the optimization of these 





In this context, it is desirable to identify biomarkers to be used prospectively for the 
selection of patients more likely to respond to single agent or the combination therapy 
and for the optimization of treatment schedules. This information might also provide 
insights about how to prevent immune related adverse events (iAEs), in particular high 
grade toxicities (≥3) observed in about 10-20% of patients treated with single agents and 
in up to 50% of cases treated with the combination. 
24
 
We recently showed that the baseline serum levels of soluble NKG2D ligands 
(sNKG2DLs) can discriminate melanoma patients treated with the combination of 




The aim of this study was to assess the value of serum levels of sNKG2DLs as 
predictors of responsiveness in melanoma patients undergoing immunotherapy regimens. 
We determined sNKG2DLs levels in pre- and post-treatment sera of melanoma patients 
treated with immune checkpoint blockade (anti-CTLA-4 or anti-PD-1 mAb monotherapy 
or their combinations) and the results were correlated with patients’ (N=194) clinical 
outcome. The same determinations were performed in a control group of melanoma 
patients treated with standard therapy or mutated BRAF inhibitors (N=65; BRAFi).  
Results 
1. Detection of sNKG2DLs in the serum of patients  
sNKG2DLs levels were recorded pre- and post-treatment (12 weeks following the 
first drug administration) in the sera of 162 melanoma patients undergoing treatment 
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with immune checkpoint blockade. The clinical and treatment characteristics of the 
patients are summarized in Table 1. MICA, MICB and ULBP-2 were detectable in a 
minority of patients at baseline (N=18, 42 and 38, respectively), Figure 1 A, B and D. 
In some patients (N=11, 19, and 10, respectively) these factors were detectable only 
in post-treatment samples. Few patients (N= 4, 8, and 2, respectively) showed ≥50% 
reduction in the concentration of these factors 12 weeks’ post-treatment. Similarly, 
increased levels of sMICA, sMICB and ULBP-2 after treatment were observed in few 
cases (N=6, 11 and 17, respectively). Higher levels of sULBP-1 and -3, were 





pg/ml (Fig. 1 C and E). Moreover, these molecules 
were most frequently found in the serum of patients both at pre- (N = 83, 62.5% and 
N= 65, 40%, respectively) and post-treatment (N= 85, 65% and N= 62, 38%) time 
points (Fig. 1 D and E). The presence of sULBP-1, due to the limiting amount of 
serum for some patients, was determined in N=131 patients. Modulation of the 
concentration of sULBPs according to treatment followed a trend like MICA and 
MICB (Fig. 1).  
Baseline levels of sNKG2DLs were also analyzed in melanoma patients not 
undergoing any immunotherapy and rather treated either with standard therapy or 
BRAFi (see Table 1 for clinical details). As shown in Figure 2, all sNKG2DLs could 
be detected in the serum of these patients (MICA in N=19, MICB in N=25, ULBP-1 
in N=32, ULBP-2 in N=20 and ULBP-3 in N=15 patients). The levels of sNKG2DLs 
were heterogeneous with peak of concentration, except for ULBP-2, lower as 
compared to patients treated with immunotherapy. Serum levels of sNKG2DLs from 
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patients treated with ipilimumab plus chemotherapy (NIBIT-M1 study; N=37) that 
have been previously described, 
25
 were also included in the subsequent analyses.  
Soluble MICA and MICB were most commonly detected in stage III melanoma 
patients (p= 0.05 and 0.001, respectively); conversely the detection of sULBP-1 was 
most frequently associated (p= 0.02) with stage IV. No associations between stage of 
the disease and detection of soluble levels of ULBP-2 and 3 were observed (data not 
shown). 
2. Identification of biomarkers of clinical outcome in melanoma patients treated 
with immune checkpoint blockade. 
Association between the presence or absence of sNKG2DLs in baseline or post-
treatment serum of melanoma patients receiving either anti-CTLA-4 or -PD-1 mAbs as 
monotherapy or their combination and clinical outcome was determined for N=194 
melanoma patients (Tables 2 and 3). This analysis included also melanoma patients 
treated with the combination of anti-CTLA-4 and fotemustine (N=37, see Table 1) for 
which the levels of sNKG2DLs and the modulation during treatment have been 
previously reported. 
25
 Disease control (DC) and OS information were available for 
N=193 and 194 patients, respectively.  
Absence of sULBP-1 in baseline serum of 77/162 evaluated patients correlated with 
better clinical outcome in terms of DC (DC rate 57.1%, p=0.002; Table 2). No 
relationship was found between the serum levels of sNKG2DLs and the clinical outcome 
of patients not treated with immunotherapy (control group; Table 2). Absence or presence 
at baseline of detectable sULBP1, respectively discriminated patients with improved (N= 
78 patients; median OS= 25.3 months; p=0.01) from poor OS (N= 85 patients; median 
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OS=12.1 months; Table 3). Similarly, lack of sMICB in pre-treatment serum identified 
patients experiencing long-term survival (N= 151 patients; median OS= 21.6 months; 
p=0.02) compared to those with detectable soluble molecules (N= 42 patients; median 
OS=8.8 months; Table 3). No relationship between serum levels of sNKG2DLs and OS 
was observed in the control group was (Table 3). 
Absent detection of sMICA and sMICB in post-treatment serum of melanoma patients 
undergoing immune checkpoint blockade correlated with improved survival (median 
OS= 20.2 and 22.8 months; p=0.02 and 0.01, respectively; Table 3) compared to cases in 
which the two factors could be detected (median OS= 12.4 and 10.4 months, 
respectively).  
No significant association between post-treatment serum levels of sNKG2D and OS of 
melanoma patients treated with BRAFi was found (Table 3). Figure 3 represents the 
Kaplan-Meier analysis of OS for melanoma patients treated either with immunotherapy 
(Panels A and B), standard therapy or BRAFi (Panels C and D) according to detection in 
baseline serum of sMICB (Panels A and C) and sULBP-1 (Panels B and D). These 
findings highlight an inverse association between levels of sNKG2DLs and the OS 
specifically in patients treated with immunotherapy. No significant association was 
detected between levels of sMICB (p=0.40) and sULBP-1 (p=0.84) and OS of patients 
who did not undergo immunotherapy (Figure 3 Panels C and D). An inverse significant 
association (p=0.02 and 0.01, respectively) between levels of sMICA and sMICB in post-
treatment serum and OS of melanoma patients treated with immunotherapy are portrayed 
by the Kaplan Meier curves in Figure 4 (Panels A and B).  
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The available cancer sets in the Cancer Genome Atlas (TCGA) were used to assess any 
relationship between the expression of NKG2DLs, that we found as candidate predictors 
for immunotherapy treatment of melanoma patients, and the clinical outcome of 30 
cohorts of patients with different types of primary tumors. The hazard ratio through COX 
analysis of the highest versus the lowest tertile of expression of these molecules was 
calculated (Figure 1S). The lowest expression of MICB was significantly associated with 
favorable clinical outcome in lower grade glioma (LGG), pancreatic adenocarcinoma 
(PADD) and thymoma patients (THYM) (p=0.000369, 0.012; and 0.0399, respectively, 
Figure 1S). Low or negative expression of ULBP-1 inversely correlated with the risk of 
death for 8 different cohorts of patients with tumors with different histological origins, 
including LGG (p=0.000131), glioblastoma (GBM; p=0.014), breast cancer (BRCA; 
p=0.0166), mesothelioma (MESO; 0.00963) (Figure 1S). Scant information is available 
in these data sets regarding metastatic melanoma patients and the therapeutic regimens 
administered to cancer patients. Although our observations couldn’t be confirmed 
through TCGA in the same setting of cancer patients, the data represented in Figure 1S 
corroborate the role of NKG2DLs as prognostic candidate biomarkers for the clinical 
outcome of cancer patients.  
3. Multivariate analysis of biomarkers  
The impact of individual and clinical parameters, such as age, LDH, PS, stage etc. (Table 
1) and the levels of sNKG2DLs in the serum of melanoma patients was evaluated by Cox 
regression analysis (Table 4). LDH was heterogeneously detected in melanoma patients 
with a range of 124-2190 IU/L and median= 302 IU/L. This molecule was reported as 
increment of 10 IU/L revealing to be the strongest (HR= 1.01, p<0.0001) prognostic 
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markers for OS survival for melanoma patients treated either with immune checkpoint 
blockade or with standard or BRAFi therapies (Table 4). PS and disease stage are 
associated with clinical benefit only for the control group (HR= 2 and 6.2 and p=0.03 and 
0.01, respectively; Table 4).  The latest two markers were not significantly associated 
(p=0.18 and 0.10, respectively) with clinical responses to immunotherapy. Interestingly, 
MICB, ULBP-1 and ULBP-2 significantly predicted clinical outcome of patients 
undergoing immunotherapy strategies (HR= 1.67 and 1.78 and p=0.02 and 0.01, 
respectively; Table 4). Multivariate COX regression analysis confirmed the role of LDH 
and ULBP-1 as independent prognostic biomarkers of the clinical outcome (HR= 1.02 
and 1.72 and p=0.02 and 0.0001, respectively; Table 4) in melanoma patients treated with 
immune checkpoint blockade. Of note, ULBP-2 also resulted as a marker associated with 
the clinical responses of this cohort of melanoma patients (HR=1.91 and p=0.02; Table 
3). The same multivariate analysis applied to the melanoma patients in the control group 
demonstrated that only LDH and age were associated with prognosis (HR= 1.03 and 
p<0.0001 and p=0.02, respectively; Table 4).  
Discussion 
In the present study, we assessed the levels of sNKG2DLs in the serum of melanoma 
patients to test whether they could represent baseline predictors of clinical outcome in 
response to treatment with immune checkpoint blockade. Absence of sMICB and 
sULBP-1 in patient’s serum at baseline distinguished long-term from poor survivors (OS 
21.6 and 25.3 vs. 8.8 and 12.1 months and p=0.02 and 0.01, respectively). In univariate 
analysis, the HR for patients with detectable levels of sMICB and/or sULBP-1 in baseline 
serum was 1.67 and 1.78, respectively (p=0.02 and 0.01, respectively). LDH was 
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confirmed as a predictive marker (HR=1.01 and p<0.0001) for the clinical outcome of 




 sULBP-1 and 
ULBP-2 were identified through multivariate analysis as candidate independent 
predictive markers (HR=1.72 and 1.91 respectively and p=0.02) of clinical response in 
patients treated with immune checkpoint inhibitors. Thus, the level of these biomarkers in 
baseline serum enables the distinction of melanoma patients with favorable clinical 
outcome from poor survivors to the treatment with immune checkpoint blockade. 





This receptor is expressed by NK, T, NKT and  T cells, providing activating signal to 
NK and co-stimulation to T cells. 
30
  Both in vitro and in vivo studies have demonstrated 
that the expression of NKG2DLs by tumor cells can lead to the efficient development of 




 NKG2DLs are expressed by tumor cells of 
different histological origin, although the surface expression of these ligands is strictly 





presence of sNKG2DLs in the serum of cancer patients has been widely documented in 








 sULBP-2 was identified as a prognostic 
factor, stronger than S100B, in early-stage (I-III) melanoma patients. 
29
 NKG2DLs can 
either promote anti-cancer immune responses or mediate immune evasion of cancer cells, 
depending upon their pattern of expression, e.g. membrane localization or proteolytic 




 sNKG2DLs can suppress anti-tumor 
immune responses through multiple mechanisms. The most common is binding of soluble 
ligands to the NKG2D receptors on T and NK cells facilitating their endocytosis and 







The suppression of anti-tumor immune responses by tumor cells secreting sMICB was 
clearly shown in a prostate cancer model of humanized transgenic mice. 
39
 sMICA can 
interfere with NK homeostatic maintenance in the peripheral blood 
39
 and can also 
promote the expansion of MDSCs. 
40
 On the other hand, high expression of membrane 
ULBP-1 positively correlated with overall survival of pancreatic cancer patients while 
sULBP-2 was found as an independent marker of poor clinical outcome for these patients  
indicating that the molecular nature of NKG2DLs can affect positively or negatively the 
clinical outcome. 
35
 The phenomenon described above might explain our observation that 
the presence of sNKG2DLs in baseline serum is associated with poor clinical outcome of 
melanoma patients treated with immunotherapy strategies. sNKG2DLs could impair anti-
tumor T cell-mediated responses thus counterbalancing the unleashing of immune 
responses by immune checkpoint blockade, such as anti-CTLA-4 or PD-1 mAbs. 
Similarly, sNKG2DLs can abolish the unlocking activity of anti-PD-1 mAbs on tumor 
reacting NK cells.   
Our preliminary analysis of cancer sets in TCGA indicated that the expression of either 
MICB or ULBP-1 was significantly associated with favorable clinical outcome of cancer 
patients with different type of tumors (e.g. LGG, PADD, THYM, GBM, BRCA, HNSC 
MESO, SARC, KIRC, KIRP, DLBC). Moreover, the highest expression of the 
activatory/co-stimulatory receptor, NKGD2, was associated with a reduced risk of death 
for cancer patients with LGG (p=1.59x10
-6
), HNSC (p=0.00029), BRCA (p=0.011), 
THYM (p=0.0064), bladder carcinoma (BLCA; p=2.02x10-8), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC; p=0.00094), lung squamous cell 
carcinoma (LUSC; p=0.0073), stomach adenocarcinoma (STAD; p=0.039), uterine 
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corpus endometrial carcinoma (UCEC; p=0.012) (Figure 1S). Interestingly, for some type 
of tumors, such as LGG, GBM, HNSC, BRCA, SARC, THYM, highest expression of 
NKG2D and lowest expression of either ULBP-1 or MICB were detected in patients with 
reduced risk of death (Figure 1S). Limited information regarding either metastatic 
melanoma patients or the therapeutic regimens received by cancer patients are included in 
the TCGA data sets, preventing us to perform any association analysis between gene 
expression of NKG2D and OS of patients treated with immune checkpoint blockade. 
Nevertheless, this exploratory analysis can corroborate the role of NKG2DLs as 
candidate predictors for the prognosis of cancer patients and the need to further 
investigate their role as biomarkers for the clinical responses to immunotherapy.  
We have previously described the role of ULBP-1 and -2 as candidate predictive 
markers for the clinical outcome of melanoma patients with metastatic disease treated 
with ipilimumab and fotemustine (NIBIT-M1 study). 
25
 These findings are substantiated 
by the present study that evaluated patients treated with immune checkpoint blockade 
both as monotherapy and in combination. In this study, we also evaluated a cohort of 
melanoma patients treated with standard therapies or BRAFi. In this context, the levels of 
sNKG2DLs did not affect clinical outcome, indicating that these molecules represent 
useful tools predicting the clinical activity of immune checkpoint blockade (see Figure 
3). We have also evaluated the relationship between the presence of sNKG2DLs in the 
serum after treatment and clinical outcome. Indeed, the absence of sMICA and sMICB in 
post-treatment serum was significantly associated (p=0.02 and 0.01, respectively) with 
improved OS (20.2 and 22.8 months, respectively) of melanoma patients undergoing anti-
CTLA-4 or anti-PD-1 mAb therapy. These results confirm the relevance of levels of 
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sNKG2DLs in pre- and post-treatment sera in predicting clinical responses in melanoma 
patient receiving immunotherapy. 
The clinical activity of ipilimumab in combination with a vaccine composed by tumor 
cells secreting GM-CSF was observed in patients with high levels of autoantibodies 
directed to MICA. 
41
 The impairment mediated by sNKG2DLs on T and NK cell-
mediated anti-tumor responses could be rescued by treatment with neutralizing 
antibodies. 
42
 Taken together these and our observations suggest a rationale to explore the 
therapeutic efficacy of the combination of immune checkpoint blockade with sNKG2DL 
neutralizing mAbs. 
43
 In addition, high sMICA levels in the serum were found to be 
associated with less frequency of immune related adverse events in a cohort of melanoma 
patients treated with ipilimumab 
44
 suggesting that sNKG2DLs can indeed play a relevant 
role in determining the fate of anti-tumor immune responses unleashed by immune 
checkpoint blocking agents. 
Our findings demonstrate that sNKG2DLs can play a role as predictive biomarkers for 
OS of melanoma patients treated with immune checkpoint blocking mAbs (including 
ipilimumab, nivolumab, pembrolizumab and their combinations) and broaden the list of 
parameters that can be worthy of monitoring in melanoma patients. Of note, these 
findings identify candidate biomarkers determinable in the serum of patients through 
assays easily accessible in different clinical centers. Further prospective investigation of 
the role of these molecules as baseline biomarkers of clinical outcome of cancer patients 
treated with immune checkpoint blockade agents and their combinations are warranted. It 
might also be interesting to elucidate the relationship that exists among gene expression 
in tumor tissues and the soluble protein levels in the serum for NKG2DLs in cancer 
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patients with different type of histology for which immunotherapy either represents a 
promising strategy or is currently under investigation. It will be worthy to assess these 
determinations in association with the extent of NKG2D expression, as a marker of 
lymphocyte infiltration, at tumor site to establish the most accurate possible biomarker 
immune signature(s) for patients undergoing immune-based therapies.  
Material and Methods 
Melanoma Patients  
Patients (N=162) with measurable unresectable stage III or stage IV melanoma were 
included in this study; see Table 1 for detailed patient’s characteristics and treatments. 
These melanoma patients have been treated with: i. ipilimumab at 3 or 10 mg/kg in the 
context of expanded access programs (EAP) or, more recently, as “on-label usage”; (N= 
132); ii. pembrolizumab for patients previously treated with ipilimumab (N=15); iii. 
monotherapy with ipilimumab or nivolumab or their combination (N=15). Moreover, 
patients treated with ipilimumab plus chemotherapy (NIBIT-M1 study; N=37) that have 
been previously described 
25
, were included in this study to carry out a more extensive 
evaluation. A control group of melanoma patients included subjects with metastatic 
disease treated either with standard chemotherapy or radiotherapy regimens (N= 31) or 
with BRAF inhibitor (BRAFi; vemurafenib or dabrafenib) -based targeted therapies 
(N=34). These patients did not ever receive any immunotherapy regimen. The therapeutic 
treatment of melanoma patients that were performed in the context of clinical studies were 
conducted in accordance with the Declaration of Helsinki and the International 
Conference on Harmonization of Good Clinical Practice and have been approved by the 
Ethics Committee of the University Hospital of Siena. An informed consent for bio-
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banking and use of biological samples and clinical data for scientific research was 
obtained from all the patients enrolled in this study. 
Response criteria were assessed according the proposed immune-related response 
criteria for immunotherapy treatments, where objective response included immune-related 
complete or partial response while disease control included immune-related confirmed 




 For patients not treated with immunotherapy, 
response criteria were assessed according WHO. Clinical responses evaluated as disease 
control (DC) and overall survival (OS) were available for from N= 193 and 194 patients, 
respectively. 
Biological samples  
Serum from melanoma patients was collected at pre-treatment (baseline) and 12 weeks 
(12W), post-treatment and then isolated by centrifugation and cryopreserved.  
Detection of sNKG2DLs in the serum of melanoma patients 
The concentration in the serum of melanoma patients (N= 162) of sNKG2DL (MICA, 
MICB, ULBP-2, ULBP-1), was assessed by the usage of ELISA kits (R&D Systems). 
Commercially available pair antibodies and related reagents (R&D Systems) were used to 
set up the ELISA assay to determine the concentration in the serum of sULBP-3. A 
standard curve with determined titrations of the recombinant human proteins allowed to 
measure sNKG2DL concentrations in the experimental samples. Data are means of 
duplicates and are represented as pg/ml. In some cases, N=100 patients, the amount of 
available serum allowed to repeat twice the Elisa assays; the inter-assay coefficient of 
variation has been calculated and was in the range of 2-8%.   Statistical analysis of 
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differences between means of concentration of NKG2DLs at different time points was 
performed using two-tailed t-test (p < 0.05). The concentration of sULBP-1 was 
determined in the baseline and W12 time points serum of N= 131 and 128 patients, 
respectively. The serum of N=10 HD was used as negative control as reported elsewhere. 
25
  
Gene expression analysis 
Expression analysis for NKG2D, MICB and ULBP-1 were obtained from available 
RNA sequencing (RNA-Seq) cancer sets in TCGA research network 
(http://cancergenome.nih.gov/) for 30 cohorts of cancer patients with different type of 
tumors.  
Statistical analysis 
Data were analyzed in a descriptive way using mean and standard deviations. This 
study was aimed at the identification of variations in candidate biomarkers previously 
identified (see ref. 25) associated with DC and OS. Association between sNKG2DLs and 
DC was assessed by chi squared test. Survival curves were estimated by the Kaplan-
Meier method and differences were evaluated with the log-rank test. Differences in OS 
according to sNKG2DLs (MICA, MICB, ULBP-1, 2, 3), gender, age, stage, LDH, PS 
were analyzed. A Cox regression analysis was implemented to investigate the role of 
each factor considered and of its relationship with the other variables in correlating with 
OS. A forward stepwise selection method was used based on Wald statistics, resulting 
models were confirmed by a backward procedure. Hazard ratio and their 95% confidence 
interval (95% CI) were reported. IBM SPSS v. 21 was used for statistical analysis. For 
TCGA data hazard ratio was calculated using R (v3.3.1) and survival package (v2.39-5). 
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The forest plot was generated using the forest plot package (v1.5.1). The Cox 
proportional hazards regression model was applied on the highest versus lowest tertiles of 
expression in each cancer cohort; p-values were calculated using pchisq function form the 
base stats package.  
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List of abbreviations 
Ab Antibody 
CTLA-4 Cytotoxic T-Lymphocyte Antigen-4 
DCR Disease Control Rate 
FBS Fetal Bovine Serum 
HS Human Serum 
mAb Monoclonal Antibody 
MICA MHC (HLA) Class I Chain-Related Gene A 
MICB MHC (HLA) Class I Chain-Related Gene B; MMA 
NKG2D the activating receptor NK cell group 2 member D (NKG2D); Rate 
OS Overall Survival 
PD-1 Programmed Cell Death -1 
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PD-L1 Programmed Cell Death Ligand 1 
ULBP-1 or -2 UL16-Binding Protein-1 or -2 
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Table 1. Clinical-pathological features of melanoma patients treated with immune checkpoint blockade agents or with 
standard/targeted therapies 
Parameter Control cohort (N=65) Immune checkpoint Cohort 
(N=162) 




 N % N % N % 
       
Men 42 65 92 57 24 65 
Women 23 35 70 43 13 35 
Median Age (years) 59 62 55 
PS       
0 24 36.9 42 25.9 33 89.2 
1 38 58.5 118 72.8 4 10.8 
2 3 4.6 2 1.2 0 0 
Median LDH 268 290 332 
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Pathological type       
Cutaneous melanoma 59 91 137 85 37 100 
Ocular melanoma 0 0 9 6 0 0 
Mucosal melanoma 2 3 12 7 0 0 
Acral melanoma  4 6 4 2 0 0 
Clinical stage       
III 12 18 7 4 1 3 
IV 53 82 155 96 36 97 
Therapeutic treatment       
ipilimumab 0 0 132 81 0 0 
ipilimumab + pembrolizumab 0 0 15 9 0 0 
Nivolumab, Ipilimumab monotherapy 
or combination 
0 0 15 9 0 0 
Ipilimumab plus chemotherapy 0 0 0 0 37 100 
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Standard therapies alone 31 48 0 0 0 0 
BRAF inhibitors 34 52 0 0 0 0 
Clinical Responses       
DCR 29  59 64 40 24 65 
Median OS (95% C.I.) 13(7.7-18.3)  13.8(10.0-17.6)  24.3(18.0-29.7)  
a
Patients were treated with the combination of ipilimumab plus fotemustine (see ref. 
46
); 
PS: Performance Status; 
LDH: Lactate Dehydrogenase 
DCR: disease control rate which includes complete responses (CR), partial responses (PR) and stable disease (SD) according the 






Table 2. Association between the levels at baseline serum of sNKG2DLs and the 
disease control of melanoma patients 
sNKG2DLs 
a










 DCR  p  
        
MICA + 22 45.7 0.99 16 32.5 0.24 
 - 171 45.6  42 45.2  
MICB + 42 42.9 0.72 19 36.8 0.16 
 - 151 46  39 56.4  
ULBP-1 + 85 32.9 0.002 35 54.3 0.42 
 - 77 57.1  23 43.5  
ULBP-2 + 45 44.4 0.86 9 44.4 0.72 
 - 148 45.9  49 51  
ULBP-3 + 77 49.4 0.39 23 43.5 0.42 
 - 116 43.1  35 54.3  
a
detection of sNKG2DLs (MICA, MICB, ULBP-1-3) in the pre-treatment serum of 
melanoma patients; positive (+) or negative (-) measurement (ng/ml) of sNKG2DLs in 
the patients’ serum;  
b
Number of subjects from the cohort of patients treated with immune checkpoint 




disease control rate (DCR) expressed as the percentage of patients with complete 
responses (CR), partial responses (PR) and stable disease (SD) according the immune 




p value obtained from Chi-squared test analysis; 
e





Table 3. Association between the levels at baseline serum of sNKG2DLs and the OS 














 OS P  
Baseline         
 MICA + 22 12.5 0.45 19 15.6 0.94 
  - 172 16.4  46 12.0  
 MICB + 43 8.8 0.02 25 13 0.4 
  - 151 21.6  40 12  
 ULBP-1 + 85 12.1 0.01 36 15.6 0.85 
  - 78 25.3  29 8.5  
 ULBP-2 + 45 9.8 0.11 9 15.6 0.77 
  - 149 20.2  56 12  
 ULBP-3 + 77 13.8 0.10 25 16 0.65 
  - 117 16.7  40 11.2  
         
W12         
 MICA + 22 12.4 0.02 11 11.1 0.18 
  - 159 20.2  13 n.r.  
 MICB + 54 10.4 0.01 11 n.r. 0.05 
  - 127 22.8  12 11.0  
 
 32 
 ULBP-1 + 80 14.7 0.17 13 11.1 0.14 
  - 70 26.3  10 n.r.  
 ULBP-2 + 49 14.7 0.27 5 15.6 0.82 
  - 132 21.6  12 24.3  
 ULBP-3 + 70 16.8 0.57 5 n.r. 0.49 
  - 106 16.7  18 13.1  
a
detection of sNKG2DLs (MICA, MICB, ULBP-1, 2, 3) in the pre- (baseline) or post- 
(W12) treatment serum of melanoma patients; positive (+) or negative (-) measurement 
(ng/ml) of sNKG2DLs are indicated;  
b
number of subjects from the cohort of patients treated with immune checkpoint blockade 
agents;  
c
OS: median overall survival expressed as months;  
d
P value obtained from log-rank test analysis; 
e
: Number of patients from the control 
cohort.  
f
W12 post-treatment data from melanoma patients treated with BRAFi; n.r.= not reached. 





Table 4. COX regression analysis to identify biomarkers influencing the clinical outcome of melanoma patients 
Marker Patient 
 Immune checkpoint Cohort Control cohort 
 Univariate analysis of factor Multivariate analysis of factor Univariate analysis of factor Multivariate analysis of factor 
 HR (CI  95%) P HR (CI  95%) P HR (CI  95%) P HR (CI  95%) P 
         
Gender 0.96 (0.69-1.33) 0.80   1.26 (0.67-2.38) 0.47   
Age 1.00 (0.99-1.01) P=0.39   1.02 (0.99-1.04) 0.16 1.03 (1.01-1.05) 0.02 
LDH 1.01 (1.01-1.02) <0.0001 1.02 (1.01-1.03) <0.0001 1.01 (1.01-1.02) <0.0001 1.02 (1.01-1.03) <0.0001 
PS 1.25 (0.90-1.72) 0.18   2.02 (1.07-3.82) 0.03   
Stage 2.63 (0.87-8.26) 0.10   6.20 (1.50-25.62) 0.01   
MICA 1.25 (0.70-2.24) 0.45   0.97 (0.50-1.91) 0.94   
MICB 1.67 (1.08-2.59) 0.02   0.75 (0.38-1.47) 0.40   
ULBP-1 1.78 (1.14-2.77) 0.01 1.72 (1.09-2.71) 0.02 0.94 (0.50-1.76) 0.84   
ULBP-2 1.42 (0.92-2.19) 0.11 1.91 (1.10-3.33) 0.02 0.88 (0.37-2.10) 0.77   
ULBP-3 1.38 (0.94-2.04) 0.10 1.38 (0.94-2.04) 0.10 0.87 (0.47-1.61) 0.65   
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The markers were determined as the following: gender: male vs. female; LDH was categorized based on increment of 10 IU/L; PS: 1, 






Figure 1. sNKG2DLs in the serum of melanoma patients treated with immune 
checkpoint blockade agents. The presence of sMICA (Panel A), sMICB (Panel B) and 
sULBP-2, 3 (Panels D and E) in the serum at baseline (black circle) and post-treatment 
(black square) of melanoma patients (N=162) treated with immune checkpoint blockade 
agents was measured by ELISA assay (see Material and Methods). ULBP-1 
determinations at pre- and post-treatment were carried out in N= 131 and 128 patients, 
respectively (Panel C). Mean and error bars are shown in the graphs. As negative control 







Figure 2: Detection of sNKG2DLs in the serum of control group melanoma patients. 
The presence of soluble NKG2DLs (MICA, Panel A; MICB, Panel B; ULBP-1, Panel C; 
ULBP-2, Panel D; ULBP-3, Panel E) was measured by ELISA assay (see Material and 
Methods) in the baseline serum (black circle) of melanoma patients (N=65) treated with 
either standard or BRAFi therapies. Mean and error bars are shown in the graphs. As 







Figure 3. Overall survival of melanoma patients treated with immunotherapy in 
relation with the presence or not of sNKG2DLs in serum. Kaplan-Meier plots of overall 
survival of melanoma patients treated with immune checkpoint blockade agents (Panels 
A and B) or with standard or BRAFi therapies (Panels C and D) in relation with the 
detection (black line) or not (dotted line) at baseline of sMICB (Panels A and C) and 
sULBP-1 (Panels B and D). The baseline serum levels of sMICB (Panel A) and ULBP-1 
(Panel B) could discriminate melanoma patients with long term survival (median OS= 
21.6 and 25.3 months, p=0.02 and 0.01, respectively) from poor survivors (median OS = 
8.8 and 12.1 months, respectively) for the cohort of patients treated with immune 
checkpoint blockade agents.  Panels C and D show the absence of association between 
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the serum levels of these ligands and OS in the control group of patients (median OS= 





Figure 4. Overall survival of melanoma patients treated with immunotherapy in 
association with the levels of sNKG2DLs in post-treatment serum. The absence (dotted 
line) in the post-treatment serum of sMICA (Panel A) and sMICB (Panel B) correlated 
with improved OS (median OS= 20.2 and 22.8 vs. 10.4 months, p=0.02 and 0.01, 
respectively) while detectable levels of these molecules were found in the serum of poor 
survivor patients (median OS=12.4 and 10.4 months, respectively) (black line).  
 
 
